A Study to Evaluate the Safety of a Delivery Device for Administering LCTOPC1 in Participants With Spinal Cord Injury

Inclusion Criteria:

1. Sensorimotor complete, traumatic SCI (ASIA Impairment Scale A) or sensoryincomplete, traumatic SCI (ASIA Impairment Scale B)

2. For subjects with subacute injury, International Standards for NeurologicalClassification of SCI (ISNCSCI) Neurological Level of Injury (NLI) from C-4 to T-10occurring 21 to 42 days prior to LCTOPC1 injection

3. For subjects with chronic injury, ISNCSCI NLI from C-4 to T-10 and more than 30 dayswithout clinical improvement from last assessment, occurring 1 to 5 years prior toLCTOPC1 injection

4. Individuals must have at least one upper extremity ISNCSCI key muscle with at least 1/5 strength

5. 18 through 65 years of age, inclusive, at time of consent

6. Single injury with sufficient visualization of the spinal cord injury epicenter andlesion margins to enable post-injection safety monitoring

7. Informed consent for this protocol must be provided and documented (i.e., signedICF)

8. Able to participate in an elective surgical procedure to inject LCTOPC1 21 days orlater following SCI

9. Female subjects of child-bearing potential must agree to the use of contraceptionfor 1 year following LCTOPC1 injection; male subjects must agree to usecontraception to prevent pregnancy in any female partners of child-bearing potentialfor 1 year following LCTOPC1 injection

Exclusion Criteria:

1. SCI due to penetrating trauma

2. Traumatic anatomical transection, laceration, or inadequate decompression of thespinal cord based on prior surgery or MRI

3. Any concomitant injury that interferes with the performance, interpretation, orvalidity of neurological examinations, such as multiple spinal cord lesions,brachial/lumbar plexus injury, cauda equina injury or traumatic brain injury

4. Subjects with a cavity structure that would preclude successful transplantation, asidentified on MRI, which may include septations or irregularities in tissuestructure

5. Persons with syringomyelia, defined as those with progressively enlarging cysts onT2-weighted images associated with neurological decline

6. Inability to communicate effectively with neurological examiner such that thevalidity of patient data could be compromised

7. Organ damage or systemic disease that would create an unacceptable risk for surgeryor immunosuppression

8. Need for mechanical support of ventilation (ventilator, continuous positive airwaypressure [CPAP], bi-level positive airway pressure [BiPAP]), excluding supplementaloxygen, at baseline

9. History of any malignancy (except non-melanoma skin cancers). For cancers inremission for more than five years, enrollment is allowed with concurred documentedapproval of principal investigator, oncologist, and Sponsor's medical monitor priorto enrollment

10. Pregnant or nursing women

11. Subjects with an implanted spinal cord stimulator (SCS), whether temporary orpermanent.